Replies to post #56 on Iovance Biotherapeutics Inc (IOVA)

[jondoeuk]

I personally can't see a buyout with the way things currently are. As for a potential buyer, it won't be GILD as they are already running a number of TCR-T cell therapy trials in a range of solid tumours (most under CRADA). I hope it would be a company with a limited IO mAb pipeline and continue with improvements, such as this https://www.globenewswire.com/news-release/2020/01/12/1969202/0/en/Iovance-Biotherapeutics-and-Cellectis-Enter-into-a-Research-Collaboration-and-Exclusive-Worldwide-License-Agreement.html